SCHEMBL3530252

SCHEMBL3530252

CC(C)c1ccc(C2(CC=O)CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TACR1 P25103 1/20 0.45
TSHR P16473 2/20 0.43
ATM Q13315 2/20 0.43
ALOX15 P16050 1/20 0.43
CCR5 P51681 6/20 0.42
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NR3C1 P04150 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
GPR119 Q8TDV5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16554221 0.88 MEN1 (0.50) HTTTACR1CCR5OPRD1OPRK1
SCHEMBL3526480 0.87 GPR119 (0.47) TACR1TSHRATMALOX15CCR5
SCHEMBL1939196 0.86 RORC (0.46) TACR1TSHRATMALOX15CCR5
SCHEMBL3272198 0.86 TACR1 (0.58) TACR1TSHRATMALOX15CCR5
SCHEMBL3530342 0.83 NPC1 (0.49) HTTNPC1ALDH1A1MAPTMAPK1
SCHEMBL27640223 0.82 ALDH1A1 (0.35) HTTNPC1ALDH1A1MAPTMAPK1
SCHEMBL3527153 0.81 TACR1 (0.46) TACR1ATMCCR5OPRD1OPRK1
SCHEMBL30479357 0.81 CCR5 (0.45) TACR1ATMCCR5OPRD1OPRK1
SCHEMBL3527380 0.81 CCR5 (0.45) TACR1ATMCCR5OPRD1OPRK1
SCHEMBL3525135 0.80 CCR5 (0.54) TACR1TSHRATMALOX15CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 HTT 4816/4885NPC1 279/4885ALDH1A1 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.